Endolysins Active Against Staphylococcus Bacteria, Pharmaceutical Compositions, and Methods Relating Thereto

Abstract

The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including isolated endolysin polypeptides from bacteriophage GRCS.

What is claimed is: 
     
         1 . A pharmaceutical composition for killing Gram-positive bacteria comprising an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or variants thereof having at least 80% identity thereto and effective for killing said bacteria, and a pharmaceutically acceptable carrier. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein said isolated polypeptide further comprises the amino acid sequence of SEQ ID NO: 7. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein said isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 5. 
     
     
         4 . The pharmaceutical composition of  claim 1 , further comprising one or more antibiotic. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein said antibiotic is selected from the group consisting of a penicillin, a cephalosporin, a polymyxin, an ansamycin, a quinolone, a sulfonamide, a lipopeptide, a glycycline, and an oxazolidinone. 
     
     
         6 . The pharmaceutical composition of  claim 4 , wherein said antibiotic is selected from the group consisting of linezolid, daptomycin, and tigecycline, vancomycin, fidaxomicin, and metronidazole. 
     
     
         7 . An isolated polypeptide capable of killing one or more strain of  Staphylococcus  bacteria, comprising the amino acid sequence of SEQ ID NO: 6 or variants thereof having at least 80% identity thereto and effective for killing said bacteria. 
     
     
         8 . The isolated polypeptide of  claim 7 , further comprising the amino acid sequence of SEQ ID NO: 7. 
     
     
         9 . The isolated polypeptide of  claim 7 , which comprises the amino acid sequence of SEQ ID NO: 5. 
     
     
         10 . A nucleic acid encoding the isolated polypeptide of  claim 7 . 
     
     
         11 . A surface of a substrate comprising an antibacterial coating, said coating comprising an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or variants thereof having at least 80% identity thereto. 
     
     
         12 . The surface of  claim 11 , wherein said isolated polypeptide further comprises the amino acid sequence of SEQ ID NO: 7. 
     
     
         13 . The surface of  claim 11 , wherein said isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 5. 
     
     
         14 . The surface of  claim 11 , wherein said coating further comprises one or more antibiotic. 
     
     
         15 . The surface of  claim 14 , wherein said antibiotic is selected from the group consisting of a penicillin, a cephalosporin, a polymyxin, an ansamycin, a quinolone, a sulfonamide, a lipopeptide, a glycycline, and an oxazolidinone. 
     
     
         16 . The surface of  claim 11 , wherein said substrate is a medical device. 
     
     
         17 . The surface of  claim 11 , wherein said substrate is an implantable medical device.